Table 3. Distribution BI-ALCL patients by Manufacturer. Note MD Anderson and USC reporting are worldwide whereas FDA MAUDE database is predominantly a United States catchment of cases.
| Institution | Manufacturer | N (%) |
|---|---|---|
| Worldwide cases by MD Anderson Tracking 2016 | Unknown | 87 (47.8) |
| Allergan/Inamed/McGhan | 76 (41.8) | |
| Mentor | 6 (3.3) | |
| Nagor | 3 (1.7) | |
| Eurosilicone | 1 (0.6) | |
| PIP | 5 (2.8) | |
| Sientra/Silimed | 3 (1.7) | |
| Bioplasty | 1 (0.6) | |
| Worldwide Cases Reported by USC 2015 | Unknown | 61 (35.0) |
| Allergan/Inamed/McGhan | 97 (56.0) | |
| Mentor | 3 (1.7) | |
| Nagor | 3 (1.7) | |
| Eurosilicone | 0 | |
| PIP | 5 (2.9) | |
| Sientra/Silimed | 1 (0.5) | |
| US MAUDE Database as of 2015 | Unknown | 22 (9.6) |
| Allergan/Inamed/McGhan | 184 (80.3) | |
| Mentor | 20 (8.7) | |
| CUI | 1 (0.4) | |
| Sientra | 1 (0.4) |